At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
sertraline +1 moredrug
Likely dose
sertraline 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness of Sertraline in Alleviating Uremic Pruritis in Hemodialysis Patients
In Brief
A Phase 2 clinical trial evaluating sertraline and placebo for Uremic Pruritis. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This study aims to assess the effect of sertraline on uremic pruritis in patients undergoing regular haemodialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUremic Pruritis
CountriesEgypt
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionSep 2022
Study CompletionOct 2022
TodayJul 2026
First PostedApr 22, 2022
Enrollment StartMay 1, 2022
Primary CompletionSep 1, 2022
Study CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.2 years ago
Interventions
sertralinedrug
sertraline at the intended dose of 50 mg twice daily for 8 weeks.
placebodrug
a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)